Oncology

Back to articles

Early lenalidomide improves multiple myeloma survival

KEY POINT

In patients with high-risk smoldering multiple myeloma, early combination therapy with lenalidomide (Revlimid—Celgene) and dexamethasone delayed disease progression and increased overall survival compared to observation. The majority of the toxic effects from the combination therapy were grade 2 or lower.

SOURCES

Mateos V et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369:438–47.

Kyle RA, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356:2582–90.